Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Study protocol

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

Authors: Christopher N Hurt, Lisette S Nixon, Gareth O Griffiths, Ruby Al-Mokhtar, Simon Gollins, John N Staffurth, Ceri J Phillips, Jane M Blazeby, Tom D Crosby

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Chemoradiotherapy is the standard of care for patients with oesophageal cancer unsuitable for surgery due to the presence of co-morbidity or extent of disease, and is a standard treatment option for patients with squamous cell carcinoma of the oesophagus. Modern regimens of chemoradiotherapy can lead to significant long-term survival. However the majority of patients will die of their disease, most commonly with local progression/recurrence of their tumours. Cetuximab may overcome one of the principal mechanisms of tumour radio-resistance, namely tumour repopulation, in patients treated with chemoradiotherapy.
The purpose of this research is first to determine whether the addition of cetuximab to definitive chemoradiotherapy for treatment of patients with non-metastatic carcinoma of the oesophagus is active (in terms of failure-free rate), safe, and feasible within the context of a multi-centre randomised controlled trial in the UK. If the first stage is successful then the trial will continue to accrue sufficient patients to establish whether the addition of cetuximab to the standard treatment improves overall survival.

Methods/Design

SCOPE1 is a two arm, open, randomised multicentre Phase II/III trial. Eligible patients will have histologically confirmed carcinoma of the oesophagus and have been chosen to receive definitive chemoradiotherapy by an accredited multidisciplinary team including a specialist Upper GI surgeon. 420 patients will be randomised to receive definitive chemoradiotherapy with or without cetuximab using a 1:1 allocation ratio.
During Phase II of the study, the trial will assess safety (toxicity), activity (failure-free rate) and feasibility (recruitment rate and protocol dose modifications/delays) in 90 patients in the experimental arm. If the experimental arm is found to be active, safe, and feasible by the Independent Data Monitoring Committee then recruitment will continue into Phase III. This second stage will recruit a further 120 patients into each arm and compare the overall survival of both groups.
All patients randomised into Phase II will contribute to the Phase III comparison of overall survival. In addition to overall survival, Phase III of the study will also assess toxicity, health related quality of life and cost effectiveness. A detailed radiotherapy protocol and quality assurance procedure has been incorporated into this trial.

Trial registration

ISRCTN: ISRCTN47718479
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global Cancer Statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
3.
Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009, 27: 5062-5067. 10.1200/JCO.2009.22.2083.CrossRefPubMed
4.
The National Oesophago-Gastric Cancer Audit: An audit of the care received by people with Oesophago-gastric Cancer in England and Wales. Third Annual Report. 2010, London, NHS Information Centre
5.
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospectice randomized trial (RTOG 85-01). Journal of the American Medical Association. 1999, 281 (17): 1623-7. 10.1001/jama.281.17.1623.PubMed
6.
Wong R, Malthaner R: Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Systematic Review. 2006, CD002092-
7.
Bedenne L, Michel P, Bouche O, Triboulet J-P, Conroy T, Pezet D, Roullet B, Seitz J-F, Lacourt J, Milan C: Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proceedings of American Society of Clinical Oncology. 2002, 21: abstr 519-Journal of Oncology
8.
Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T: Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. Clinical Oncology (Royal College of Radiologists (Great Britain)). 2011, 23 (3): 182-188. 10.1016/j.clon.2010.12.001.CrossRef
9.
Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D, Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E: Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clinical Oncology (Royal College of Radiologists (Great Britain)). 2003, 15 (3): 98-108. 10.1053/clon.2003.0212.CrossRef
10.
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Groups 94-05) phase III trials of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. Journal of Clinical Oncology. 2002, 20 (5): 1167-74. 10.1200/JCO.20.5.1167.CrossRefPubMed
11.
Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New England Journal of Medicine. 2006, 326 (24): 1593-8.CrossRef
12.
Stahl M, Wilke H, Walz MK: A Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: Chemoradiation with and without surgery. Proceeding of the Annual Meeting of the American Society of Clinical Oncology (ASCO), Journal of Oncology. 2003, 22: abstr 1001-
13.
Gill V, Melcher A, Crellen A: Chemoradiotherapy for Oesophageal Cancer: The Leeds Cancer Centre Experience. Clinical Oncology (Royal College of Radiologists (Great Britain)). 2003, 15:
14.
Tsutsumi K, Yasuda M, Nishioka T: X-ray irradiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line. Cell Structure and Function. 2006, 31 (2): 47-52. 10.1247/csf.31.47.CrossRefPubMed
15.
Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and × rays. International Journal of Radiation Oncology, Biology, Physics. 1982, 8 (11): 1923-33. 10.1016/0360-3016(82)90451-5.CrossRefPubMed
16.
Button M, Staffurth J, Crosby T: National variations in the treatment of oesophageal carcinoma with chemo-radiotherapy. Clinical Oncology. 2007, 19 (3 Suppl): S25.-
17.
Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, NCRI Upper GI Study Group: Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. Proceeding of the Annual Meeting of the American Society of Clinical Oncology (ASCO), Journal of Clinical Oncology. 2006, 24: abstrLBA4017-
18.
Das P, Wolff RA, Abbruzzese JL, Krishnan S, Varadhachary GR, Xiong HQ, Evans DB, Vauthey JN, Baschnagel A, Crane CH: Concurrent capecitabine and upper abdominal radiation therapy is well-tolerated. Proceeding of the American Society of Clinical Oncology (ASCO)GI cancers symposium. Journal of Clinical Oncology. 2006, abstr106-
19.
Morgan C, Brewster AE, Maughan TS, Harvey-Jones A, Crosby TDL: Patterns of failure after definitive chemo-radiation for inoperable carcinoma of the oesophagus. Clinical Oncology. 2004, 16: S15.2-CrossRef
20.
Steel GG: Basic Clinical Radiobiology. Edited by: Gordon Steel G. 2002, 3
21.
Baumann M, Krause M: Targeting the epidermal growth factor receptor in radiotherapy: radiological mechanism, preclinical and clinical results. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2004, 72 (3): 257-66. 10.1016/j.radonc.2004.07.007.CrossRef
22.
Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997, 15 (10): 1191-7. 10.1038/sj.onc.1201275.CrossRefPubMed
23.
Bonner JA, Harari PM, Giralt JL, Azarnia N, Shin DM, Cohen RB, Joes CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amella N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2006, 354 (6): 567-78. 10.1056/NEJMoa053422.CrossRefPubMed
24.
Kies MS, Harris J, Rotman MZ, et al: Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). International Journal of Radiation Oncology Biology Physics. 2009, 75 (3): S15-CrossRef
25.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastic colorectal cancer. The New England Journal of Medicine. 2004, 351 (4): 337-45. 10.1056/NEJMoa033025.CrossRefPubMed
26.
Dewdney A, Capdevila J, Glimelius B, Cervantes A, Tait DM, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates JR, Chau I, Cunningham D: EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. Journal Clinical Oncology. 2011, 29: abstr 3513-CrossRef
27.
Rischin D, Burmeister B, Mitchell P, Boyer M, Macmanus M, Walpole E, Feigen M, Tin MM, Ball D: Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. Journal of Clinical Oncology. 2004, 22 (14S): abstract7077-
28.
Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R: Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of Clinical Oncology. 2011, 29 (17): 2312-8. 10.1200/JCO.2010.31.7875.CrossRefPubMedPubMedCentral
29.
Enzinger PC, Yock T, Suh W, et al: Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Journal of Clinical Oncology. 2006, 24 (18): abstr 4064-
30.
Thomas CR, Goldman BH, Benedetti JK, Lenz HJ, Beeker T, Abbruzzese JL, Blanke CD: Cetuximab plus cisplatin, irinotecan and thoracic radiotherapy (TRT) as definitive treatment for locally advanced, unresectable esophageal cancer (EC): a SWOG (S0414) phase II trial. Proceedings of the. 2010, Orlando, abstract no. 72, Jan 15-17. 2010 (Poster presentation), Gastrointestinal Cancers Symposium
31.
Suntharalingam M, Dipetrillo T, Akerman P, Wanebo H, Daly B, Doyle LA, Krasna MJ, Kennedy T, Safran H: Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer. Proceeding of the Annual Meeting of the American Society of Clinical Oncology (ASCO). Journal of Clinical Oncology. 2006, 24 (18S): Abstr4029-
32.
Dobelbower MC, Russo SM, Raisch KP, Seay LL, Clemons LK, Suter S, Posey J, Bonner JA: Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs. 2006, 17 (1): 95-102. 10.1097/01.cad.0000185178.26862.4c.CrossRefPubMed
33.
Gibson MK, Catalano P, Kleinberg LR, Staley CA, Montgomery EA, Song W, Mulcahy MF, Leichman LP, Benson AB: E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. Journal of Clinical Oncology. 2010, 28 (15s): Abst.4064-
34.
Lledo G, Michel P, Dahan L, et al: Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). Journal of Clinical Oncology. 2011, 29 (4): abstr 8-
35.
Lim JT, Truong PT, Berthelet E, Pai H, Joe H, Wai E, Larsson S, Kader HA, Weinerman B, Wilson K, Olivotto IA: Endoscopic response predicts for survivial and organ preservation after primary chemoradiotherapy for esophageal cancer. International Journal of Radiation Oncology, Biology, Physics. 2003, 57 (5): 1328-35. 10.1016/S0360-3016(03)00751-X.CrossRefPubMed
36.
Hui R, Bull CA, Gebski V, O'Rouke I: Radiotherapy and concurrent chemotherapy for oesophageal carcinoma. Australas Radiology. 1994, 38 (4): 315-9. 10.1111/j.1440-1673.1994.tb00208.x.CrossRef
37.
Gill PG, Jamieson GG, Denham J, Devitt PG, Ahmed A, Yeoh E, Jones AM: Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy. British Journal of Surgery. 1990, 77: 1020-1023. 10.1002/bjs.1800770922.CrossRefPubMed
38.
Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tapper JE: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. Journal of Clinical Oncology. 1996, 14 (1): 156-63.PubMed
39.
John MJ, Flam MS, Mowry PA, Podolsky WJ, Xavier AM, Wittlinger PS, Padmanabhan A: Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer. 1989, 63 (12): 2397-403. 10.1002/1097-0142(19890615)63:12<2397::AID-CNCR2820631204>3.0.CO;2-S.CrossRefPubMed
40.
Poplin EA, Khanuja PS, Kraut MJ, Herskovic AM, Lattin PB, Cummings G, Gaspar LE, Kinzie JL, Steiger Z, Vaitkevicius VK: Chemoradiotherapy of esophageal carcinoma. Cancer. 1994, 74 (4): 1217-24. 10.1002/1097-0142(19940815)74:4<1217::AID-CNCR2820740407>3.0.CO;2-O.CrossRefPubMed
41.
Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J: Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterolgie Clinique et Biologique. 1995, 19 (5): 465-74.
42.
Brown WA, Thomas J, Gotley D, Burmeister B, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM: Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. British Journal of Surgery. 2004, 91 (2): 199-204. 10.1002/bjs.4411.CrossRefPubMed
43.
Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V: Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. Journal of Clinical Oncology. 2003, 21 (3): 428-32. 10.1200/JCO.2003.04.013.CrossRefPubMed
44.
Barthel FMS, Royston P, Babiker A, UK Medical Research Council: A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: update. The Stata Journal. 2005, 5 (1): 129-9.
45.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PE, Schraub S, Sneeuw K, Sullivan M, Takeda F: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of National Cancer Inst. 1993, 85 (5): 365-376. 10.1093/jnci/85.5.365.CrossRef
46.
Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, Arraras J, Bottomley A, Vickery CW, Etienne PL, Alderson D, European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups: Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. European Journal of Cancer. 2003, 39 (10): 1384-94. 10.1016/S0959-8049(03)00270-3.CrossRefPubMed
47.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994, 19 (3): 210-6. 10.1111/j.1365-2230.1994.tb01167.x.CrossRefPubMed
48.
Lewis V, Finlay AY: 10 years experience with the dermatology life quality index (DLQI). Journal of the Investigational Dermatological Symposium Porceedings. 2004, 9 (2): 169-80. 10.1111/j.1087-0024.2004.09113.x.CrossRef
49.
Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A: EORTC QLQ-C30 Scoring Manual. 2001, 0-86.
Metadata
Title
SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus
Authors
Christopher N Hurt
Lisette S Nixon
Gareth O Griffiths
Ruby Al-Mokhtar
Simon Gollins
John N Staffurth
Ceri J Phillips
Jane M Blazeby
Tom D Crosby
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-466

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells

Research article

Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells

Research article

Measuring cancer care coordination: development and validation of a questionnaire for patients

Research article

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

Research article

Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells

Research article

Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits